Company intelligence / Profile preview

IRX Therapeutics, Inc.

New York City, New York, United Stateseternatx.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 2

Overview

IRX-2 (citoplurikin) showed positive results in Phase 2 clinical trials for head and neck cancer. In a Phase 1b trial for early stage breast cancer, IRX-2 was well-tolerated with no Grade 3 or 4 toxicities and showed encouraging signs of activity including upregulation of PD-L1. The company has initiated a Phase 2 clinical trial of IRX-2 in combination with pembrolizumab (Keytruda) and chemotherapy in triple negative breast cancer.

Therapeutic areas: OncologyInfectious Diseases
Modalities: Cytokine-based therapyImmunotherapyCell-derived biologics
Industry: Biotech

Drug pipeline

1 asset

IRX-2

Phase 2

Indications: Cancer, Viral diseases

Partnerships

Providence Cancer Institute

Beyond the preview

Go deeper on IRX Therapeutics, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IRX Therapeutics, Inc..

Explore the full profile